NCT04965792Active, not recruiting
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Circulating HPV DNA for Post-treatment Surveillance in HPV-positive Oropharyngeal Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 19 Apr 2021
- Start date
- 19 Nov 2020
- Primary completion date
- Nov 2026
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Head and neck cancer
- NCT number
- NCT04965792
What you commit to
- Study type: Observational
- Planned participants: 150
- From 19 Nov 2020 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Distant metastatic disease (M1, AJCC 8th edition)
Who the study is looking for
- Participants must have histologically or cytologically confirmed incident or recurrent squamous cell carcinoma of the tonsil or base of tongue (oropharynx) - includes biopsy of any lymph node with clinical evidence of an oropharynx tumor (unknown primary carcinoma in an involved cervical neck lymph node is permitted if high-risk HPV testing is positive on the involved node)
- HPV-associated tumor as defined by one or more : positive p16 immunohistochemistry (\>70%) OR in situ hybridization OR PCR-based methods
- Age 18 years or older
- Will undergo oropharyngeal cancer treatment with curative intent
- Ability to understand and the willingness to sign a written informed consent document.
- Baseline positive or detectable ctHPV DNA result in plasma OR detectable corresponding HPV DNA in tumor tissue prior to treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.